Fig. 4
Summary of peripheral immunological features associated with Nab-paclitaxel + pembrolizumab response in HR+ breast cancer.
Fig. 4 | npj Breast Cancer
Summary of peripheral immunological features associated with Nab-paclitaxel + pembrolizumab response in HR+ breast cancer.
